Corticosteroid Therapy in the Age of Infliximab: Acute and 1-Year Outcomes in Newly Diagnosed Children With Crohn’s Disease  James Markowitz, Jeffrey Hyams, David Mack, Neal LeLeiko, Jonathan Evans, Subra Kugathasan, Marian Pfefferkorn, Adam Mezoff, Joel Rosh, Vasundhara Tolia, Anthony Otley, Anne Griffiths, M. Susan Moyer, Maria Oliva–Hemker, Robert Wyllie, Robert Rothbaum, Athos Bousvaros, J. Fernando Del Rosario, Sandra Hale, Trudy Lerer  Clinical Gastroenterology and Hepatology  Volume 4, Issue 9, Pages 1124-1129 (September 2006) DOI: 10.1016/j.cgh.2006.05.011 Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 1 Percent of the population on continuous corticosteroid therapy over time. Clinical Gastroenterology and Hepatology 2006 4, 1124-1129DOI: (10.1016/j.cgh.2006.05.011) Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 2 One-year response to corticosteroid (CS) treatment as a function of 3-month response. cs, corticosteroid. ▩, Surgery; □, CS dependent; ▨, prolonged response. Clinical Gastroenterology and Hepatology 2006 4, 1124-1129DOI: (10.1016/j.cgh.2006.05.011) Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 3 Summary of acute and 1-year outcomes. Clinical Gastroenterology and Hepatology 2006 4, 1124-1129DOI: (10.1016/j.cgh.2006.05.011) Copyright © 2006 American Gastroenterological Association Terms and Conditions